| 9.35 0.09 (0.97%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.43 | 1-year : | 12.26 |
| Resists | First : | 9.79 | Second : | 10.5 |
| Pivot price | 9.21  |
|||
| Supports | First : | 8.64 | Second : | 7.19 |
| MAs | MA(5) : | 9.14  |
MA(20) : | 9.28 |
| MA(100) : | 9.65 |
MA(250) : | 9.63 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 57.9 |
D(3) : | 45.7 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 16.66 | Low : | 4.32 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRTA ] has closed below upper band by 32.7%. Bollinger Bands are 42% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.45 - 9.48 | 9.48 - 9.51 |
| Low: | 8.84 - 8.88 | 8.88 - 8.92 |
| Close: | 9.28 - 9.34 | 9.34 - 9.4 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Sat, 17 Jan 2026
Prothena Corp (PRTA) Analyst Ratings: RBC Capital's New Price Ta - GuruFocus
Fri, 16 Jan 2026
Prothena announces board of directors update - MSN
Tue, 13 Jan 2026
How Prothena Corporation Plc (PRTA) Affects Rotational Strategy Timing - Stock Traders Daily
Fri, 02 Jan 2026
(PRTA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Sun, 21 Dec 2025
Squarepoint Ops LLC Takes $1.27 Million Position in Prothena Corporation plc $PRTA - MarketBeat
Fri, 07 Nov 2025
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 4.339e+007 (%) |
| Held by Institutions | 19.2 (%) |
| Shares Short | 4,660 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2135e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 646.4 % |
| Return on Equity (ttm) | -29.4 % |
| Qtrly Rev. Growth | 1.179e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -188 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 4.7e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|